<DOC>
	<DOCNO>NCT00855894</DOCNO>
	<brief_summary>This Phase II , open-label , single-arm , single-stage , multicenter trial patient relapse non-small cell lung cancer ( NSCLC ) , objective assessing activity combination erlotinib pertuzumab basis endpoint FDG-PET response rate .</brief_summary>
	<brief_title>A Study Combination Erlotinib Pertuzumab Patients With Relapsed Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically confirm nonsmall cell lung cancer ( NSCLC ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Recurrent progressive disease receive least 1 , two , chemotherapy regimen advance metastatic NSCLC . Recovery reversible acute effect prior anticancer therapy ( chemotherapy , radiotherapy , investigational treatment ) National Cancer InstituteCommon Terminology Criteria Adverse Events ( NCICTCAE ) Grade ≤ 1 ( exclude alopecia ) . Ability comply study followup procedure , include specify imaging study . Ability take oral medication . Life expectancy ≥ 3 month . Measurable disease compute tomography ( CT ) . At least 1 extracerebral lesion 2deoxy2 [ 18F ] fluoroDglucosepositron emission tomography ( FDGPET ) scan suitable response assessment , measurable , ≥ 15 mm CT. Left ventricular ejection fraction ( LVEF ) ≥ 50 % , determine echocardiogram MUltiple Gated Acquisition ( MUGA ) scan . For woman childbearing potential men partner childbearing potential , agreement use highly effective nonhormonal form contraception two effective form nonhormonal contraception patient and/or partner . Availability willingness provide sufficient tumor tissue test epidermal growth factor receptor ( EGFR ) mutation , human epidermal growth factor receptor ( HER ) pathway NSCLCrelated biomarkers . Prior treatment investigational market agent purpose inhibit HER family member ( include HER1 , HER2 , HER3 , HER4 ) . This include , limited erlotinib , gefitinib , pertuzumab , cetuximab , panitumumab . Chemotherapy , radiotherapy , investigational treatment within 28 day start study ( ie , prior Day 0 ) patient yet recover . Inability take oral medication , disease affect gastrointestinal absorption , prior surgical procedure affect gastrointestinal absorption . Uncontrolled diabetes . Clinical radiographic evidence new progression preexist central nervous system ( CNS ) metastases . Current severe , uncontrolled systemic disease ( eg , clinically significant cardiovascular , pulmonary , metabolic disease ; woundhealing disorder ; ulcer ; bone fracture ) . Current uncontrolled hypertension unstable angina . History congestive heart failure ( CHF ) New York Heart Association ( NYHA ) criterion , serious cardiac arrhythmia require treatment ( exception : atrial fibrillation , paroxysmal supraventricular tachycardia ) . History myocardial infarction within 6 month enrollment history unstable angina . Any evidence unstable infection suggest infectious process , couple hypotension and/or tachycardia and/or fever and/or positive blood culture . Known human immunodeficiency virus ( HIV ) infection . Uncontrolled hypercalcemia . Pregnancy lactation . History another malignancy past 2 year , unless malignancy adequately treat , currently detectable , associated 5year survival &gt; 90 % . Claustrophobia . Any disease , condition , physical examination finding , clinical laboratory finding , opinion investigator , make patient inappropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Tarceva</keyword>
	<keyword>NSCLC</keyword>
</DOC>